WO2015079413A3 - Synaptojanin-2 inhibitors for use in the treatment of cancer - Google Patents

Synaptojanin-2 inhibitors for use in the treatment of cancer Download PDF

Info

Publication number
WO2015079413A3
WO2015079413A3 PCT/IB2014/066404 IB2014066404W WO2015079413A3 WO 2015079413 A3 WO2015079413 A3 WO 2015079413A3 IB 2014066404 W IB2014066404 W IB 2014066404W WO 2015079413 A3 WO2015079413 A3 WO 2015079413A3
Authority
WO
WIPO (PCT)
Prior art keywords
synaptojanin
inhibitors
cancer
treatment
general formula
Prior art date
Application number
PCT/IB2014/066404
Other languages
French (fr)
Other versions
WO2015079413A2 (en
Inventor
Yosef Yarden
Nir Ben-Chetrit
Original Assignee
Yeda Research And Development Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IL2013/050986 external-priority patent/WO2014083567A2/en
Application filed by Yeda Research And Development Co. Ltd. filed Critical Yeda Research And Development Co. Ltd.
Priority to US15/100,322 priority Critical patent/US20170042857A1/en
Priority to EP14827537.3A priority patent/EP3074044A2/en
Publication of WO2015079413A2 publication Critical patent/WO2015079413A2/en
Publication of WO2015079413A3 publication Critical patent/WO2015079413A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Disclosed herein are synaptojanin-2 inhibitors, and novel methods and uses utilizing same for preventing tumor metastasis, treating cancer or inhibiting synaptojanin-2. Compounds disclosed herein include chlorhexidine and pyrvinium, the compound having the formula: (I) and compounds characterized by the general formula: X-L-[(Y)i-(Z)j]-(L-X)k and/or by the general formula:(II) wherein L, X, Y, Z, D, E, i, j and k are as defined herein.
PCT/IB2014/066404 2012-11-29 2014-11-27 Synaptojanin-2 inhibitors and uses thereof WO2015079413A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US15/100,322 US20170042857A1 (en) 2012-11-29 2014-11-27 Synaptojanin-2 inhibitors for use in the treatment of cancer
EP14827537.3A EP3074044A2 (en) 2013-11-28 2014-11-27 Synaptojanin-2 inhibitors and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361910086P 2013-11-28 2013-11-28
PCT/IL2013/050986 WO2014083567A2 (en) 2012-11-29 2013-11-28 Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors
ILPCT/IL2013/050986 2013-11-28
US61/910,086 2013-11-28

Publications (2)

Publication Number Publication Date
WO2015079413A2 WO2015079413A2 (en) 2015-06-04
WO2015079413A3 true WO2015079413A3 (en) 2015-08-13

Family

ID=53199695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/066404 WO2015079413A2 (en) 2012-11-29 2014-11-27 Synaptojanin-2 inhibitors and uses thereof

Country Status (2)

Country Link
EP (1) EP3074044A2 (en)
WO (1) WO2015079413A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107898799A (en) * 2017-11-20 2018-04-13 中国科学院昆明植物研究所 Applications of the Paeonivayin in the medicine for preparing treatment central nervous system disease
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
CN111217790B (en) * 2020-02-19 2022-09-13 南昌大学 Preparation and application of phenolic acetal derivative
CN116421590B (en) * 2023-06-14 2023-08-29 深圳市第二人民医院(深圳市转化医学研究院) Application of chlorhexidine diacetate in preparing medicine for preventing or/and treating liver cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008523A (en) * 2004-06-22 2006-01-12 Lb Maple Treat Inc Physiologically active phenolic compound and food containing the same
EP2119434A1 (en) * 2008-05-13 2009-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of heterosidic flavonoid derivatives for therapy of stem cell cancers
KR20100138398A (en) * 2009-06-25 2010-12-31 건국대학교 산학협력단 Composition comprising 3-o-glucose-isorhamnetin as an effective ingredient for treatment and prevention of inflammatory diseases, immune diseases or cancers
WO2012144711A2 (en) * 2011-04-20 2012-10-26 한국과학기술연구원 Composition containing caryopteris incana extracts or a compound isolated therefrom for preventing and treating hepatotoxicity
WO2014083567A2 (en) * 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008523A (en) * 2004-06-22 2006-01-12 Lb Maple Treat Inc Physiologically active phenolic compound and food containing the same
EP2119434A1 (en) * 2008-05-13 2009-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of heterosidic flavonoid derivatives for therapy of stem cell cancers
KR20100138398A (en) * 2009-06-25 2010-12-31 건국대학교 산학협력단 Composition comprising 3-o-glucose-isorhamnetin as an effective ingredient for treatment and prevention of inflammatory diseases, immune diseases or cancers
WO2012144711A2 (en) * 2011-04-20 2012-10-26 한국과학기술연구원 Composition containing caryopteris incana extracts or a compound isolated therefrom for preventing and treating hepatotoxicity
WO2014083567A2 (en) * 2012-11-29 2014-06-05 Yeda Research And Development Co. Ltd. Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BODMER ALEXANDRE ET AL: "Anticorps et tumeurs solides: cibles établies et pistes prometteuses // The potential of monoclonal antibodies in cancer : established trastuzumab and cetuximab and promising targets IGF-1R and c-MET", M/S MEDECINE SCIENCES, vol. 25, no. 12, 1 December 2009 (2009-12-01), SOCIETE DES PERIODIQUES FLAMMARION, PARIS, FR, pages 1090 - 1098, XP009141211, ISSN: 0767-0974 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 13 January 2006 (2006-01-13), ARIHARA, SHIGENOBU ET AL: "Phenol compounds from maple plant as health foods for prevention and treatment of diabetes, obesity and cancer", XP002738087, retrieved from STN Database accession no. 2006:31344 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 5 April 2010 (2010-04-05), CUI, CHENGBIN ET AL: "Extraction method of galloyl glucopyranose compounds from Chinese medicine Choerospondias and its application as antitumor and anti-hypoxic agents", XP002738088, retrieved from STN Database accession no. 2010:418008 *
DATABASE WPI Week 201276, Derwent World Patents Index; AN 2012-N95709, XP002738089 *
FENG NI ET AL: "Flavonoid Ampelopsin Inhibits the Growth and Metastasis of Prostate Cancer In Vitro and in Mice", PLOS ONE, vol. 7, no. 6, E38802, 5 June 2012 (2012-06-05), pages 1 - 9, XP055098872, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0038802 *
ITO HIDEYUKI ET AL: "Anti-tumor promoting activity of polyphenols from Cowania mexicana and Continue and Coleogyne ramosissima", CANCER LETTERS, NEW YORK, NY, US, vol. 143, no. 1, 23 August 1999 (1999-08-23), pages 5 - 13, XP009147210, ISSN: 0304-3835, [retrieved on 19990723], DOI: 10.1016/S0304-3835(99)00160-3 *
PONOU B K ET AL: "Dimeric antioxidant and cytotoxic triterpenoid saponins from Terminalia ivorensis A. Chev", PHYTOCHEMISTRY, vol. 71, no. 17-18, 1 December 2010 (2010-12-01), PERGAMON PRESS, GB, pages 2108 - 2115, XP027491126, ISSN: 0031-9422, [retrieved on 20101111], DOI: 10.1016/J.PHYTOCHEM.2010.08.020 *
TANIMURA S ET AL: "Suppression of tumor cell invasiveness by hydrolyzable tannins (plant polyphenols) via the inhibition of matrix metalloproteinase-2/-9 activity", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 330, no. 4, 20 May 2005 (2005-05-20), pages 1306 - 1313, XP004844871, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2005.03.116 *
YA-YU CHUANG ET AL: "Role of Synaptojanin 2 in Glioma Cell Migration and Invasion Updated version", CANCER RESEARCH, 15 November 2004 (2004-11-15), pages 8271 - 8275, XP055098695, Retrieved from the Internet <URL:http://cancerres.aacrjournals.org/content/64/22/8271.full.pdf> [retrieved on 20140127] *

Also Published As

Publication number Publication date
EP3074044A2 (en) 2016-10-05
WO2015079413A2 (en) 2015-06-04

Similar Documents

Publication Publication Date Title
EA201792205A1 (en) HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
MX2016002544A (en) Compounds useful as immunomodulators.
EA201391626A1 (en) COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-STIMULATED CANCER TYPES
PH12016500225B1 (en) Novel quinoline-substituted compound
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2022000517A (en) Substituted tricyclic compounds as fgfr inhibitors.
UA111382C2 (en) Protein kinase inhibitors
MX2016006432A (en) Tetrahydro-benzodiazepinones.
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
UA113470C2 (en) PIRIMIDINE AND PORIDINE COMPOUNDS AND THEIR APPLICATIONS
EA201200102A1 (en) COMPOUNDS APPLICABLE AS A MEDICINE
MX2016005383A (en) Compositions for treating subterranean formations.
PH12015501088A1 (en) Dimeric compounds
WO2014089177A3 (en) Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
MX2014003376A (en) Benzoic acid derivatives as eif4e inhibitors.
PH12015501038A1 (en) Inhibitors of iap
MX2021016058A (en) Antitumoral compounds.
MX2021003843A (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer.
MX2015013936A (en) Substituted condensed pyrimidine compounds.
WO2015079413A3 (en) Synaptojanin-2 inhibitors for use in the treatment of cancer
MX2016007810A (en) N1-(3,3,3-trifluoro-2-hydroxo-2-methylpropionyl)-piperidine derivatives as inhibitors of pyruvate dehydrogenase kinase.
MX2015005753A (en) Antimicrobial agents.
PH12015500399A1 (en) Azaindolines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14827537

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15100322

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2014827537

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2014827537

Country of ref document: EP